GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AngioDynamics Inc (NAS:ANGO) » Definitions » Equity-to-Asset
中文

AngioDynamics (AngioDynamics) Equity-to-Asset : 0.67 (As of Feb. 2024)


View and export this data going back to 2004. Start your Free Trial

What is AngioDynamics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. AngioDynamics's Total Stockholders Equity for the quarter that ended in Feb. 2024 was $218.7 Mil. AngioDynamics's Total Assets for the quarter that ended in Feb. 2024 was $324.8 Mil. Therefore, AngioDynamics's Equity to Asset Ratio for the quarter that ended in Feb. 2024 was 0.67.

The historical rank and industry rank for AngioDynamics's Equity-to-Asset or its related term are showing as below:

ANGO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.67   Med: 0.74   Max: 0.89
Current: 0.67

During the past 13 years, the highest Equity to Asset Ratio of AngioDynamics was 0.89. The lowest was 0.67. And the median was 0.74.

ANGO's Equity-to-Asset is ranked better than
53.45% of 870 companies
in the Medical Devices & Instruments industry
Industry Median: 0.65 vs ANGO: 0.67

AngioDynamics Equity-to-Asset Historical Data

The historical data trend for AngioDynamics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioDynamics Equity-to-Asset Chart

AngioDynamics Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.74 0.77 0.78 0.77 0.71

AngioDynamics Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.73 0.71 0.87 0.80 0.67

Competitive Comparison of AngioDynamics's Equity-to-Asset

For the Medical Instruments & Supplies subindustry, AngioDynamics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AngioDynamics's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AngioDynamics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where AngioDynamics's Equity-to-Asset falls into.



AngioDynamics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

AngioDynamics's Equity to Asset Ratio for the fiscal year that ended in May. 2023 is calculated as

Equity to Asset (A: May. 2023 )=Total Stockholders Equity/Total Assets
=378.296/532.637
=0.71

AngioDynamics's Equity to Asset Ratio for the quarter that ended in Feb. 2024 is calculated as

Equity to Asset (Q: Feb. 2024 )=Total Stockholders Equity/Total Assets
=218.698/324.842
=0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AngioDynamics  (NAS:ANGO) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


AngioDynamics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of AngioDynamics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


AngioDynamics (AngioDynamics) Business Description

Traded in Other Exchanges
Address
14 Plaza Drive, Latham, NY, USA, 12110
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. It generates maximum revenue from Endovascular Therapies. Geographically, the company derives a majority of its revenue from the United States.
Executives
Lorinda Burgess director 22 WEST FRONTAG ROAD, NORTHBROOK IL 60093
Karen A Licitra director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Michael E Tarnoff director C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Scott Centea officer: SVP/GM, VIT C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Dave Helsel officer: SVP Global Operations and R&D 400 WOOD ROAD, BRAINTREE MA 02184
Laura Piccinini officer: SVP International C/O ANGIODYNAMICS INC., 14 PLAZA DRIVE, LATHAM NY 12110
Stephen A Trowbridge officer: SVP and General Counsel 14 PLAZA DRIVE, LATHAM NY 120110
James C Clemmer director, officer: President and CEO COVIDIEN PLC, 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Wesley Johnson director
Chad Thomas Campbell officer: SVP/GM, Vascular Access 140 POKANOKET PATH, WRENTHAM MA 02093
Warren Jr Nighan officer: SVP Quality and Regulatory ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Richard C Rosenzweig officer: SVP and General Counsel C/O DENTSPLY SIRONA INC., 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kevin J Gould director 247 WASHINGTON STREET, DUXBURY MA 02332
Brent J. Boucher officer: SVP and GM of Oncology 14 PLAZA DRIVE, LATHAM NY 12110
Michael Greiner officer: EVP and CFO C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421